Company Research Report: BenevolentAI

Company Overview

• Name: BenevolentAI

• Mission: The company focuses on AI-enabled drug discovery, aiming to leverage data and AI to accelerate scientific advances in drug discovery and improve the probability of clinical success, delivering life-changing treatments to patients.

• Founded: No information is available

• Founder(s): No information is available

• Key People:

• Kenneth Mulvany - Executive Chairman

• Peter Allen - Non-Executive Director and Deputy Chair

• Michael Brennan - Executive Director

• Prof Sir Nigel Shadbolt - Non-Executive Director

• Ian Nicholson - Non-Executive Director

• Jeremy Sohn - Non-Executive Director

• Headquarters: London, UK at 4-8 Maple Street, London W1T 5HD

• Number of Employees: No information is available

• Revenue: No information is available

• Company Recognition:

• Known for being a leader in applying advanced AI to accelerate drug discovery.

• Collaborates with major biopharma companies like AstraZeneca and Merck.

Products

Benevolent Platform™

• Description: This is an AI-enabled drug discovery engine designed to unlock the power of a vast biomedical data landscape. It provides a multidimensional representation of human biology across all diseases, enhancing drug discovery and development.

• Key Features:

• Empowers scientists by augmenting human intelligence.

• Enables better understanding of disease mechanisms.

• Facilitates discovery of novel drug targets.

• Aids in decision-making with greater confidence.

Recent Developments

• Collaborations:

• AstraZeneca: Ongoing multi-year collaboration focusing on chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). Progress has been made in Heart Failure and Systemic Lupus Erythematosus (SLE) targets as well.

• Merck: New multi-year collaboration to identify and develop innovative compounds. This collaboration initially focuses on three novel small molecule drug candidates in oncology, neurology, and immunology.

• Pipeline Progress:

• Five advanced clinical and preclinical assets are progressing toward their next inflection points.

• Lead asset BEN-8744 is currently in Phase I clinical study for ulcerative colitis, with topline data expected in Q1 2024.

• Leadership Appointment:

• Kenneth Mulvany appointed as Executive Chairman as of 17 October 2024.

• Events and Conferences:

• Presentation on explainable AI for drug discovery took place at BioTechX Europe 2024.

• Participation in panels such as the Morgan Stanley 3rd Annual Life Sciences AI Summit and Goldman Sachs 45th Annual Global Healthcare Conference.

• Company Culture:

• BenevolentAI emphasizes a culture of collaboration between scientists and technologists, aiming to transform drug discovery and development processes.

Contact Information

• Headquarters Address: 4-8 Maple Street, London W1T 5HD, UK

• Wet Labs Location: Babraham Campus, Cambridge CB22 3AT

• Registered Address: 9 rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg

Please note that some details such as founding information, exact number of employees, and revenue are not readily available from the provided data.